Lilly's GLP-1 business beat again, and Wall Street raised its number

Eli Lilly's stock outlook rises after another beat-and-raise quarter driven by strong GLP-1 sales, with analysts seeing room for further gains.

Aug 07, 2026

Eli Lilly had another strong quarter, and Wall Street responded by raising its price target on the stock. The company's GLP-1 business keeps outperforming expectations, which is reshaping how investors, employers, and patients think about these drugs. For readers, that means wider access through new retail partners, along with real questions about cost and safety that are playing out in courtrooms, boardrooms, and personal stories alike.

Analysts raised their price target on Eli Lilly's stock after the company delivered another beat-and-raise quarter, with GLP-1 drugs Mounjaro and Zepbound driving revenue well above expectations. The strength of this business suggests the stock still has room to grow, according to the firms tracking it closely. Lilly's newly launched obesity pill Foundayo also contributed to the results in its first quarter on the market. This performance widens the gap between Lilly and its main competitor, Novo Nordisk, which is still working to win back market share and rebuild investor confidence in its own pipeline.

Amazon Pharmacy has joined the group of major providers offering GLP-1 weight loss drugs for $50 a month under a program that continues to expand across the pharmacy industry. The move gives patients another option beyond traditional retail pharmacies and may pressure competitors to match the price point or lose customers. For readers who have struggled with the list price of these medications, this kind of program can make treatment more affordable if their insurance does not cover it. I would suggest checking whether Amazon Pharmacy's program applies to your specific medication and dosage before switching providers, since eligibility rules vary by drug and manufacturer.

Gracie McGraw, daughter of country singer Tim McGraw, says she started taking Ozempic to manage symptoms of polycystic ovary syndrome, but the drug brought back an eating disorder she had previously worked to overcome. She eventually stopped taking the medication because of this effect. McGraw has spoken out against promoting thinness as a goal, a message that adds a personal voice to the ongoing conversation about how GLP-1 drugs interact with mental health and body image. Her account is a reminder that these medications can affect people differently, and anyone with a history of disordered eating may want to raise that history with their doctor before starting treatment.

Bank of America now spends more than $250 million a year covering GLP-1 drugs such as Ozempic, Wegovy, and Zepbound for its employees. CEO Brian Moynihan has called this spending a good investment, framing it as a benefit that pays off for the company as well as its workforce. The bank's decision reflects a broader shift among large employers, who have had to grapple with soaring demand for these drugs even as the per-patient cost can reach thousands of dollars a year. Not every employer has responded the same way. Some smaller organizations, including at least one county government, have introduced monthly employee co-pays specifically to control GLP-1 spending, which shows how differently employers of varying sizes are handling the same cost pressure.

A federal judge dismissed a lawsuit that accused Eli Lilly and Novo Nordisk of illegally blocking access to compounded, customized versions of their GLP-1 drugs. The suit had been brought by a compounding drug maker, and its dismissal is a legal win for both pharmaceutical companies as they continue to defend the market for their branded products. This decision follows a similar ruling in the Netherlands, where a Dutch court banned sales of an unapproved compounded semaglutide nasal spray after Novo Nordisk won a patent infringement case. Together, these rulings suggest that compounders may face a harder path forward as brand-name manufacturers push back through the courts rather than through pricing alone.

Taken together, these developments show a market that is both expanding and coming under more scrutiny. Prices are coming down in some retail channels, and employers are recalculating what they are willing to spend, while legal decisions are narrowing the options available to compounders. If you are currently taking or considering a GLP-1 drug, it is a good time to compare pricing options like Amazon Pharmacy's program against what your insurance already covers, and to talk with your doctor about your personal health history, including any past eating disorders, before starting or continuing treatment.

Key details

Eli Lilly's stock price target just rose again after another strong quarter beat,…
Amazon Pharmacy now offers GLP-1 weight loss drugs for $50 under a program spreading…
Gracie McGraw says Ozempic revived her eating disorder while treating PCOS, prompting…
Bank of America now spends over $250 million yearly on GLP-1 drugs for employees,…
A federal judge dismissed a lawsuit accusing Lilly and Novo Nordisk of blocking access…

Sources

Originally published on GLP-1 Nation

Discussion about this post

Ready for more?